BTIG analyst Ryan Zimmerman assigned a Buy rating to Integra Lifesciences (NASDAQ: IART) yesterday and set a price target of $69. The company’s shares closed yesterday at $64.08, close to its 52-week high of $67.50.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 28.7% and a 70.5% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, OrthoPediatrics Corp, and Stryker Corporation.
Integra Lifesciences has an analyst consensus of Hold, with a price target consensus of $65.67.
See today’s analyst top recommended stocks >>
Based on Integra Lifesciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $11.38 million. In comparison, last year the company had a net profit of $10.84 million.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.
